MYX 3.29% $4.40 mayne pharma group limited

Ann: Non-Executive Director retirement, page-26

  1. 1,371 Posts.
    lightbulb Created with Sketch. 263
    We will see how ridiculous it is next week.
    This company has a long standing habit of
    overpaying and overspending. The cash shown
    there isn’t surplus. Even though they have reduced
    Mithra holdings by 50% they gave away 10% for only
    $27,5m. They will have spent a small fortune marketing
    Nextellis , Annovera and the like. They require extra
    $$ should we take on Donesta for US distribution.
    as we will definitely receive Nil assistance in Marketing
    costs to establish the product mainly because the
    owner Mithra is basically broke. The previous products
    we have tried to sell (Nextellis and Haloette) were
    the main cause for Mayne having to sell its biggest
    asset. Check the Liabilities column Hadrian . It is
    growing.
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.